OLX-07010 Active

Phase 1Small molecule

OOligomerix, Inc

OLX-07010 Active is one of 50 small molecule programs targeting Alzheimer disease. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Alzheimer DiseaseActive, not recruiting

Alzheimer DiseasePhase 1

Active, not recruiting

Competition

Competitive Landscape

91 competitors in Alzheimer Disease

#DrugCompanyPhaseTrials

Aleve

Estrace

Avandia

Depakote

Keppra

Farxiga

Cialis

Rifadin

Epidiolex

Mifeprex

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Alzheimer disease1 trial

Phase 1 Randomized, Double-Blind, Single Ascending Dose, Multiple Ascending Dose, and Food Effect Study of the Safety, Tolerability, and Pharmacokinetics of OLX-07010 in Healthy Adult and Elderly Participants

Active, not recruiting·OOligomerix, Inc·Phase 1·NCT05696483·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for OLX-07010 Active. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OLX-07010 Active compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OLX-07010 Active. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Oligomerix, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: OOligomerix, Inc

OLX-07010 Active

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Alzheimer disease1 trial

References

Drug Info

Quick Facts

Related News